GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » PE Ratio without NRI

CARsgen Therapeutics Holdings (HKSE:02171) PE Ratio without NRI : At Loss (As of Mar. 04, 2025)


View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings PE Ratio without NRI?

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2025-03-04), CARsgen Therapeutics Holdings's share price is HK$15.74. CARsgen Therapeutics Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1.35. Therefore, CARsgen Therapeutics Holdings's PE Ratio without NRI for today is At Loss.

CARsgen Therapeutics Holdings's EPS without NRI for the six months ended in Jun. 2024 was HK$-0.68. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1.35.

As of today (2025-03-04), CARsgen Therapeutics Holdings's share price is HK$15.74. CARsgen Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1.35. Therefore, CARsgen Therapeutics Holdings's PE Ratio (TTM) for today is At Loss.

CARsgen Therapeutics Holdings's EPS (Diluted) for the six months ended in Jun. 2024 was HK$-0.68. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1.35.

CARsgen Therapeutics Holdings's EPS (Basic) for the six months ended in Jun. 2024 was HK$-0.68. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1.35.


CARsgen Therapeutics Holdings PE Ratio without NRI Historical Data

The historical data trend for CARsgen Therapeutics Holdings's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings PE Ratio without NRI Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio without NRI
N/A N/A At Loss At Loss At Loss

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of CARsgen Therapeutics Holdings's PE Ratio without NRI

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CARsgen Therapeutics Holdings's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's PE Ratio without NRI falls into.



CARsgen Therapeutics Holdings PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

CARsgen Therapeutics Holdings's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=15.74/-1.345
=-11.7(At Loss)

CARsgen Therapeutics Holdings's Share Price of today is HK$15.74.
For company reported semi-annually, CARsgen Therapeutics Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.35.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


CARsgen Therapeutics Holdings  (HKSE:02171) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


CARsgen Therapeutics Holdings PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


CARsgen Therapeutics Holdings Business Description

Traded in Other Exchanges
N/A
Address
No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America.
Executives
Candock Holdings Limited 2501 Other
Yang Xuehong 2501 Other
Quan Zhou Shi Ding Wo Chuang Feng Tou Zi Zhong Xin You Xian He Huo 2501 Other
Yi De Kong Gu You Xian Gong Si 2501 Other
Yi Jie Sheng Wu Ji Shu Kong Gu You Xian Gong Si 2501 Other
Accure Biotech Limited 2501 Other
Wang Huamao 2401 A concert party to an agreement to buy shares
Li Zonghai 2401 A concert party to an agreement to buy shares
Guo Huaqing 2101 Beneficial owner
Guo Bingsen 2401 A concert party to an agreement to buy shares
Redelle Holding Limited 2501 Other
He Xi Holdings Limited 2501 Other
Guo Xiaojing 2501 Other
Chen Haiou 2501 Other
Cart Biotech Limited 2501 Other

CARsgen Therapeutics Holdings Headlines

No Headlines